In the double-FIT strategy, the colorectal cancer prevalence was 0.17 per cent where both tests were negative, 2.3 per cent if only one was positive and 19.9 per cent if both had values of 10 μg Hb per g or greater. The gene discussed is GSTM1; the disease is colorectal cancer.